Controls serum phosphorus levels. Sold as Auryxia. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Ferric Citrate (sold as Auryxia), first approved Sep 5, 2014, with 1 new use approved and 0 published complete response letters.
| Auryxia | Part D | $357K | -100% | 178 |
| Ferric Citrate | Part D | $163K | New | 79 |
| Ferric Citrate in Iron Deficiency Anemia During PregnancyAnemia · Dhaka Medical College | Phase 3 | Recruiting | Feb 2, 2026 |
| Ferric Citrate and Chronic Kidney Disease in ChildrenChronic Kidney Diseases · University of California, Los Angeles | Phase 2 | Recruiting | Feb 5, 2021 |
| Ferric Citrate in ESRD Pilot ProjectEnd Stage Renal Disease, Chronic Kidney Diseases · Sreedhar Mandayam | Phase 4 | Active, not recruiting | Feb 16, 2017 |
| Sep 5, 2014 | AuryxiaNDA 205874 · New formulation or manufacturer | Keryx Biopharms | 13 | Marketed |
| Mar 11, 2026 | Ferric CitrateANDA 212563 | Teva Pharms USA | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
